#1Passion for Innovation. Compassion for Patients™M FY2022 Q3 Financial Results Presentation DAIICHI SANKYO CO., LTD. Hiroyuki Okuzawa Director, Senior Executive Officer, CFO January 31, 2023 Daiichi-Sankyo#2Forward-Looking Statements Daiichi-Sankyo Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward-looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward. Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation. Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof. The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain. This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion. Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information. 2#3Agenda 1 FY2022 Q3 Financial Results 2 Business Update 3 R&D Update 4 Appendix Daiichi-Sankyo 3#4Overview of FY2022 Q3 Results coll FY2021 Q3 FY2022 Q3 YoY (Bn JPY) YTD Results YTD Results +16.9% Revenue 811.0 948.3 137.3 Cost of sales * 263.2 257.4 -5.8 SG&A expenses * 255.7 330.8 75.1 R&D expenses ✶ 169.1 241.7 72.6 Core operating profit * 123.0 118.3 -3.8% -4.7 Temporary income* 2.1 11.0 8.9 Temporary expenses * 1.3 2.2 0.9 Operating profit 123.8 +2.7% 127.1 3.4 Profit before tax 125.9 127.5 1.6 Profit attributable to owners 94.3 86.7 -8.1% -7.6 of the Company Currency Rate USD/JPY EUR/JPY 111.10 130.62 136.53 140.60 +25.43 +9.98 Daiichi-Sankyo *As an indicator of ordinary profitability, "core operating profit” which excludes temporary income and expenses from operating income is disclosed. Income and expenses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses". Temporary income and expenses are excluded from results and forecast for cost of sales, SG&A expenses and R&D expenses shown in the list above. The adjustment table from operating profit to core operating profit is stated in the reference data 4#5Revenue Increased by 137.3 Bn JPY (Increased by 65.0 Bn JPY excl. forex impact) Daiichi-Sankyo Positive Factors (Bn JPY) Negative Factors FY2021 Q3 YTD Results Japan Business 811.0 Japan Business Unit Lixiana +9.1 Nexium (incl. Innovative Pharmaceuticals, 22.2 Tarlige +6.3 Loxonin -39.6 -2.8 Generic, Vaccines, OTC) Gains on sales of products in US +3.5 Oncology Business*1 52.3 Gains on sales of products in EU- +2.6 American Regent 1.2 Oncology Business*1 Unit Enhertu +62.8 Transferred products -7.1 EU Specialty Business 6.8 ASCA American Regent Unit 10.3▸ (Asia, South and Central America) Venofer Enhertu, Dato-DXd*2 HBT products +5.8 +3.3 Injectafer -8.3 16.6 Upfront Payment & Regulatory Milestone Forex Impact*3 FY2022 Q3 YTD Results 72.3 948.3 Positive Factors Negative Factors EU Specialty Business Unit Lixiana +7.2 Gain on sales of transferring long-listed products -1.4 Enhertu, Dato-DXd"² Upfront Payment & Regulatory Milestone Enhertu Regulatory Milestone - +15.7 *1 Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products *2 Dato-DXd: Datopotamab deruxtecan (DS-1062) *3 Forex impact USD: +49.4, EUR: +9.7, ASCA: +13.2 5#6Core Operating Profit Decreased by 4.7 Bn JPY (Decreased by 1.5 Bn JPY excl. forex impact) FY2021 Q3 YTD Results 123.0 Revenue 137.3 Cost of Sales SG&A Expenses R&D Expenses Forex Impact 75.6 FY2022 Q3 YTD 118.3 Results 45.3 Positive Factors 42.4 Revenue +137.3 incl. forex impact of +72.3 Cost of Sales -21.4 Improvement in cost of sales ratio by change in product mix 21.4 SG&A Expenses Negative Factors +42.4 Daiichi-Sankyo (Bn JPY) Increase in expenses related to Enhertu due to an increase in profit share of gross profit with AstraZeneca R&D Expenses +45.3 Increase in 3ADCS* R&D investments Forex Impact +75.6 (Profit Decreased) Cost of Sales +15.6 SG&A Expenses +32.7 R&D Expenses +27.3 * 3ADCs: 1) Enhertu, Trastuzumab deruxtecan (T-DXd, DS-8201), 2) Datopotamab deruxtecan (Dato-DXd, DS-1062) and 3) Patritumab deruxtecan (HER3-DXd, U3-1402) 6#7Profit Attributable to Owners of the Company Decreased by 7.6 Bn JPY FY2021 Q3 YTD 94.3 Results Core Operating Profit Temporary Revenue/ Expenses Financial Income/ Expenses etc. 4.7 8.0 Daiichi-Sankyo (Bn JPY) Temporary Income/Expenses +8.0 (Profit increased) FY2021 Q3 YTD FY2022 Q3 YTD YOY Temporary Income 2.1*1 11.0*2 +8.9 Temporary Expenses 1.3 2.2 +0.9 *1 Gains related to sale of Osaka logistics center (2.1) *2 Gains related to sales of subsidiary of Daiichi Sankyo (China) (6.0) Gains on reversal related to closure of Plexxikon (3.3) Financial Income/Expenses etc. +1.7 (Profit Decreased) • Deterioration in forex gains/losses +1.4 1.7 Income Taxes etc. 9.2 Income Taxes etc. +9.2 FY2022 Q3 YTD 86.7 Results FY2021 Q3 YTD FY2022 Q3 YTD YOY Profit before Tax Positive Factors Negative Factors Income Taxes etc. Tax rate 125.9 31.6 25.1% 127.5 40.8 32.0% +1.6 +9.2 +6.9% 7#8Revenue: Business Units (incl. Forex Impact) (Bn JPY) 0000 Japan Business Daiichi Sankyo Healthcare FY2021 Q3 YTD Results FY2022 Q3 YTD Results YOY 393.7 356.4 -37.3 49.7 54.8 +5.1 Oncolgy Business 49.2 124.7 +75.6 Enhertu 36.6 122.1 +85.5 Turalio 2.0 2.7 +0.6 American Regent 115.6 143.5 +27.9 Injectafer 42.3 41.8 -0.5 Venofer 25.2 38.2 +12.9 GE injectables EU Specialty Business 41.7 51.6 +9.9 97.9 112.5 +14.6 Lixiana 74.3 87.8 +13.5 Nilemdo/Nustendi 2.2 4.9 +2.6 Olmesartan 14.9 14.8 -0.1 ASCA (Asia, South and Central America) Business 82.9 106.4 +23.5 Currency Rate Daiichi-Sankyo USD/JPY 111.10 136.53 +25.43 EUR/JPY 130.62 140.60 +9.98 8#9Revenue: Major Products in Japan (Bn JPY) coll FY2021 Q3 FY2022 Q3 YOY YTD Results YTD Results Lixiana anticoagulant 70.5 79.5 +9.1 Tarlige pain treatment 22.8 29.1 +6.3 Pralia treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis 28.7 30.4 +1.7 Efient antiplatelet agent 12.7 15.7 +3.0 Tenelia type 2 diabetes mellitus treatment 18.6 17.0 -1.6 Vimpat anti-epileptic agent 13.9 16.7 +2.8 treatment for bone complications caused by bone Ranmark 15.6 15.6 -0.0 metastases from tumors Canalia type 2 diabetes mellitus treatment 13.0 12.5 -0.5 Loxonin anti-inflammatory analgesic 17.6 14.7 -2.8 anti-cancer agent Enhertu 6.9 8.5 +1.5 (HER2-directed antibody drug conjugate) Emgality prophylaxis of migraine attacks 3.4 4.7 +1.3 Daiichi-Sankyo 9#10Agenda 1 FY2022 Q3 Financial Results 2 Business Update 3 R&D Update 4 Appendix Daiichi-Sankyo 10#11ENHERTU Revenue 0000 FY2022 Q3 YTD Results FY2022 Forecast YoY vs. Forecast as of Oct. (Bn JPY) <Reference> Total Consideration Product Sales Japan US Europe ASCA 139.7 96.2 200.4 5.1 8.5 1.5 12.4 -3.6 99.8 68.2 141.6 4.6 22.3 17.4 32.8 2.6 9.2 9.2 13.6 1.5 *1 *1 Upfront payment 7.4 9.8 149.0 *1 *1 Regulatory milestone payment 19.7 18.0 26.6 5.1 126.2 US HER2+ Breast Cancer 3L 0.7 0.9 13.7 EU HER2+ Breast Cancer 3L 0.4 0.5 7.9 US HER2+ Gastric Cancer 2L + 3L 0.6 - 0.8 12.1 US HER2+ Breast Cancer 2L 3.2 3.2 3.5 13.1 EU HER2+ Breast Cancer 2L 2.5 2.5 2.7 10.1 US HER2-low Breast Cancer (post-chemo) 6.8 6.8 7.3 27.7 EU HER2-low Breast Cancer (post-chemo) *2 5.1 5.1 19.5 EU HER2+ Gastric Cancer 2L 1.2 1.2 1.3 -0.0 4.8 US HER2 Mutant NSCLC 2L 4.3 4.3 4.6 17.3 Quid related payment *1 0.9 -2.3 1.1 *1 17.2 Sales milestone payment 13.0 -1.0 13.0 *2 * 3 Total 167.6 112.0 250.9 9.2 305.5 Daiichi-Sankyo *1 Revenue recognized in each period *2 Converted with assumed forex rate for Q4 (Jan. Mar. 2023) of 130 JPY to 1 USD - (Forecast as of October was converted with assumed forex rate of 140 JPY to 1 USD) *3 Milestone of 100Mn USD for achieving annual product sales of 1 Bn USD in co- commercialization territory with AstraZenceca. (Total revenue expected to be recognized in FY2022) Ref. Total sales milestone payment: 1.75 Bn USD (Max) 11#12ENHERTU Sales Increase since Launch Steady increase in product sales due to market penetration and additional indications ENHERTU trastuzumab deruxtecan HER2+ BC 2L HER2-low BC US Europe Japan ASCA HER2+ BC 3L HER2+ GC 3L HER2+ BC 3L HER2+ BC 3L HER2+ GC 2L HER2+ BC 3L HER2+ BC 2L HER2+ BC 2L HER2 mutant NSCLC 2L FY2022 Q3 product sales: 60.2 Bn JPY FY2019Q4 FY2020 Q1 FY2020 Q2 FY2020 Q3 FY2020 Q4 FY2021 Q1 FY2021 Q2 FY2021 Q3 FY2021 Q4 FY2022 Q1 FY2022 Q2 FY2022 Q3 Daiichi-Sankyo New indications approved in FY2022 Q3 HER2 low BC HER2+ BC 2L HER2+ GC 2L 12#13ENHERTU Performance in Each Region (US, EU) Steady increase in product sales due to market penetration and additional indications Global product sales: FY2022 Q3 YTD results 139.7 Bn JPY (YOY +96.2 Bn JPY) 200.4 Bn JPY (YOY +135.0 Bn JPY) FY2022 forecast Daiichi-Sankyo US Product sales: FY2022 Q3 YTD results 99.8 Bn JPY (731 Mn USD) 141.6 Bn JPY (1,050 Mn USD) FY2022 forecast Indication: HER2+ BC 2L/3L, HER2 low BC (post-chemo), HER2+ GC 2L, HER2 mutant NSCLC 2L Market share status ➤ HER2+ BC 2L/3L: Maintaining No.1 new patient share HER2 low BC: Achieved No.1 new patient share HER2+ GC 2L: Maintaining No.1 new patient share HER2 mutant NSCLC 2L: Good uptake in the population Other progress ➤ Approved for HER2+ BC 2L and started promotion (May 2022) Classified as a category 1 preferred regimen for patients with tumors that are HER2 IHC 1+ or 2+ and ISH negative in NCCN*1 guidelines (Jun. 2022) Approved for HER2 low BC (post chemo) and HER2 mutant NSCLC 2L and started promotion (Aug. 2022) *1 NCCN: National Comprehensive Cancer Network Blue letters: updates from Q2 Europe Product sales: FY2022 Q3 YTD results 22.3 Bn JPY (163 Mn USD) FY2022 forecast 32.8 Bn JPY (243 Mn USD) Indication: HER2+ BC 2L/3L, HER2 low BC (post-chemo), HER2+ GC 2L Market share status ➤ HER2+ BC 2L: Increasing significantly in launched countries/regions (No.1 in France) ➤ HER2+ BC 3L: Maintaining No.1 new patient share Other progress (UK, France, Germany) ➤ Approved for HER2+ BC 2L and started promotion (Jul. 2022) ➤ Approved for HER2+ GC 2L and started promotion (Dec. 2022) Launched in Spain (Dec. 2022) Approved for HER2 low BC (post-chemo) and started promotion (Jan. 2023) >ENHERTU trastuzumab deruxtecan Ⓡ 13#14ENHERTU Performance in Each Region (Japan, ASCA) Steady increase in product sales due to market penetration and increasing launched countries/regions Global product sales: FY2022 Q3 YTD results 139.7 Bn JPY (YOY +96.2 Bn JPY) FY2022 forecast Japan 200.4 Bn JPY (YOY +135.0 Bn JPY) Product sales: FY2022 Q3 YTD results 8.5 Bn JPY FY2022 forecast 12.4 Bn JPY ASCA Product sales: FY2022 Q3 YTD results 9.2 Bn JPY FY2022 forecast 13.6 Bn JPY Indication: HER2+ BC 2L/3L, HER2+ GC 3L Market share status HER2+ BC 3L: Maintaining No.1 new patient share ➤ HER2+ GC 3L: Maintaining No.1 new patient share Other progress ➤ Classified as a preferred regimen for HER2+ BC 2L treatment in guidelines in Japan (Jun. 2022) ➤ Approved for HER2+ BC 2L and started promotion (Nov. 2022) Indication: HER2+ BC 2L/3L, HER2 low BC (post-chemo), HER2+ GC 3L Market share status Sales growing in Brazil, Hong Kong and Taiwan Other progress ➤ Launched in Taiwan (Apr. 2022) Launched in Korea (Jan. 2023) Blue letters: updates from Q2 Daiichi-Sankyo ENHERTUⓇ trastuzumab deruxtecan 14#15Other Initiatives in Each Region JPN Europe/ ASCA Anticancer agent EZHARMIAⓇ launched in Dec. 2022 ➤ Indication: Relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) ➤ MOA: Dual EZH1 and EZH2* inhibitor ➤ Administration: Usually, dosage for adult is 200 mg of valemetostat orally administered once daily on an empty stomach. The dose should be reduced as appropriate according to the patient's condition *Histone methyltransferase involved in hematological cancer progression 0 ·抗限性場剂 EZHI/2關書 「エザルミア錠50mg バレメトスタットトシル -> 50mg 抗燃性寫潮 EZHI/2黑 Daiichi-Sankyo 10錠 10% バレメトスタットトシル酸塩錠 「エザルミア錠100mg 100mg EZHARMIAⓇ Tablet 50mg, 100mg Agreement with Kite Pharma, Inc.: MA Transfer of Human Cell Therapy Product YESCARTAⓇ R ➤ Objective: Expansion of access to YESCARTA ® therapy ➤ Transfer to: Gilead Sciences, K.K. (an affiliate of Kite Pharma, Inc.) Timing: In CY 2023 ➤Financials: DS to receive a royalty on product sales and a sales milestone payment CLEAR Outcomes trial of lipid-lowering treatment NILEMDOⓇ met the primary study endpoint. The trial has been designed to evaluate if bempedoic acid reduces CV events in high- and very high-risk patients who tolerate no or very low doses of statin (Jan. 2023) CLEAR Outcomes study ➤ event-driven, randomized, multicenter, double-blind, placebo-controlled Ph3 study led by Esperion Therapeutics, Inc. The primary endpoint was relative risk reduction in major adverse cardiovascular events (MACE-4*) ➤ Comprehensive data will be presented at a key medical congress * Composite of the time to first cardiovascular death, nonfatal myocardial infarction, non-fatal stroke, or coronary revascularization 15#16ENHERTU® Business Briefing Sunao Manabe President and CEO Date and time 2023 March (TBD) Meeting style Virtual (Zoom) Ken Keller Global Head, Oncology Business Unit Daiichi-Sankyo 16#17Agenda 1 FY2022 Q3 Financial Results 2 Business Update 3 R&D Update 4 Appendix Daiichi-Sankyo 17#183ADCs Update Alpha Update News Flow Daiichi-Sankyo 18#19ENHERTUⓇ Progression-Free Survival Probability, % DESTINY-Breast03 Study SABCS 2022 Efficacy (PFS) Efficacy (OS) T-DXd T-DM1 T-DXd T-DM1 100- Median (95% CI), months 28.8 (22.4-37.9) 6.8 (5.6-8.2) T-DXd: 94.1% (95% CI, 90.4-96.4) T-DM1: 86.0% (95% CI, 81.1-89.8) 100- 80 T-DXd: 75.2% (95% CI, 69.3-80.2) T-DM1: 33.9% (95% CI, 27.7-40.2) HR P 0.33 (95% CI, 0.26-0.43) <0.000001a,b T-DXd: 53.7% (95% CI, 46.8-60.1) T-DM1: 26.4% (95% CI, 20.5-32.6) 60 40 ++ 20 0 1 Censor T-DXD (n = 261) T-DM1 (n = 263) 2 3 4 5 67 8 Overall Survival Probability,% T-DXd: 77.4% (95% CI, 71.7-82.1) T-DM1: 69.9% (95% CI, 63.7-75.2) Median (95% CI), months NR (40.5-NE) NR (34.0-NE) 80- HR P 0.64 (95% CI, 0.47-0.87) 0.0037a,b 60 40 0 Censor T-DXd (n = 261) T-DM1 (n = 263) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 Anti-cancer therapies in post trial setting: T-DXd arm: 64/182 (35.2%) received T-DM1 ⚫ T-DM1 arm: 42/243 (17.3%) received T-DXd 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Time, months DESTINY-Breast03 Study Time, months Comparative study of ENHERTUⓇ and T-DM1 as a 2nd line treatment in patients with HER2 positive recurrent metastatic BC ENHERTUⓇ reduced the risk of death by 36% (HR: 0.64) ■mPFS with ENHERTUⓇ was 4 times longer than with T-DM1 (28.8 months vs. 6.8 months) ■ORR was 78.5%; 1 in 5 (21%) patients experienced CR Data Cutoff: July 25, 2022 The safety profile observed with ENHERTU® in DESTINY-Breast03 was consistent with previous clinical trials with no new safety concerns identified Groundbreaking survival supports ENHERTUⓇ as the 2L SOC in HER2+ BC BC: breast cancer, Cl: confidence interval, CR: complete response, HR: hazard ratio, ILD: interstitial lung disease, mPFS: median progression-free survival, ORR: objective response rate, OS: overall survival, PFS: progression-free survival, NE: not estimable, NR: not reached, SABCS: San Antonio Breast Cancer Symposium, SOC: standard of care, T-DM1: trastuzumab emtansine, T-DXd: trastuzumab deruxtecan Daiichi-Sankyo 19#20ENHERTU DESTINY-Breast02 Study SABCS 2022 Reconfirm favorable benefit-risk profile as a 3L treatment of HER2 positive BC Progression-Free Survival Probability, % 100- 80 T-DXd: 62.3% (95% CI, 57.0-67.1) TPC: 27.2% (95% CI, 20.1-34.8) 60- 40- 20- Censor T-DXD (n = 406) TPC (n = 202) PFS T-DXd: 42.2% (95% CI, 36.5-47.8) TPC: 13.9% (95% CI, 7.9-21.6) ㄒㄒ Median (95% CI), months T-DXd 17.8 (14.3-20.8) 6.9 (5.5-8.4) TPC HR (95% CI): 0.3589 (0.2840-0.4535) P<0.000001 DESTINY-Breast02 Study Daiichi-Sankyo Comparative study of ENHERTU ® and TPC as a 3rd line treatment in patients with HER2 positive recurrent metastatic BC ■ENHERTUⓇ demonstrated statistically significant and clinically meaningful improvement in PFS and OS vs. TPC for patients with HER2+ BC previously treated with T-DM1 . mPFS: T-DXd (17.8 months) vs. TPC (6.9 months) . MOS: T-DXD (39.2 months) vs. TPC (26.5 monthes) 100 Overall Survival Probability, % 60 10 40 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 Time, months T-DXd: 89.4% (95% CI, 85.9-92.1) TPC: 74.7% (95% CI, 67.4-80.4) 20 0 OS T-DXd: 65.9% (95% CI, 60.7-70.7) TPC: 54.3% (95% CI, 46.3-61.6) +-+-+-+--+-----+ ■Overall safety profile was consistent with the established safety of ENHERTUⓇ, with no new safety signals observed Censor T-DXd (n = 406) TPC (n = 202) I I Median (95% CI), months T-DXd TPC 39.2 (32.7-NE) 26.5 (21.0-NE) HR (95% CI): 0.6575 (0.5023-0.8605) P=0.0021a 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 Time, months Data cutoff: June 30, 2022 BC: breast cancer, Cl: confidence interval, HR: hazard ratio, NE: not estimable, mOS: median overall survival, mPFS: median progression-free survival, OS: overall survival, PFS: progression-free survival, SABCS: San Antonio Breast Cancer Symposium, T-DM1: trastuzumab emtansine, T-DXd: trastuzumab deruxtecan, TPC: treatment of physician's choice 10 20#21ENHERTU® Gastric Cancer Update ENHERTU® was approved in the EU for patients with HER2+ unresectable advanced/recurrent gastric cancer in Dec 2022 Approval was based on the results from Ph2 study for 2nd line treatment in unresectable advanced/recurrent gastric cancer (DESTINY-Gastric02 in North America and Europe) and Ph2 study for 3rd line treatment (DESTINY-Gastric01 in Japan and Korea) DESTINY-Gastric02 data presented at ESMO 2022 ■ORR (Primary endpoint): 41.8% (95% CI: 30.8-53.4) ■DOR: 8.1 months (95% CI: 5.9-NE) ■ Safety profile was generally consistent with the established safety profile of ENHERTU® ■ Approval for the 2nd cancer type following breast cancer by EMA Daiichi-Sankyo CI: confidence interval, DoR: duration of response, EMA: European Medicines Agency, ESMO: European Society for Medical Oncology, NE: not estimable, ORR: objective response rate 21#22ENHERTU® Clinical and Regulatory Progress HER2+ breast cancer, 2L ■Nov 2022: Approval in Japan HER2 low breast cancer, post-chemo ■Dec 2022: Recommended for approval in EU by CHMP Jan 2023: Approval in EU HER2 mutant NSCLC, 2L+ ■Dec 2022: Filing accepted in Japan ■Jan 2023: Filing accepted in EU Daiichi-Sankyo CHMP: Committee for Medicinal Products for Human Use, NSCLC: non-small cell lung cancer 22#23Best percentage change in SOD from baseline by BICR Best percentage change in SOD from baseline by BICR (n=39)* Dato-DXd 100- 80- 60- 40 20 0 -20 -40. -60 -80 -100- 100- 50 -50- TROPION-PanTumor01 Study SABCS 2022, HR positive and HER2 low or negative BC Cohort Efficacy Antitumor Responses by BICR (n=39) a Postbaseline tumor assessments were not available for 1 patient at data cutoff. One patient was not confirmed to have a target lesion per BICR and therefore had a best overall response of non-CR/non-PD. Ongoing -100- 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Time, weeks Data Cutoff: July 22, 2022 TROPION-PanTumor01 Daiichi-Sankyo HR positive and HER2 low or negative BC Cohort Cohort of patients with HR positive and HER2 low or negative unresectable or metastatic BC in Ph1 trial to: evaluate safety and efficacy of Dato-DXd ■Dato-DXd showed encouraging and durable efficacy in patients with HR positive and HER2 low or negative BC who previously received median of 5 lines of treatment for metastatic disease • • Confirmed ORR and DCR were 27% and 85%, respectively mPFS was 8.3 months 95% patients were pretreated with CDK4/6 inhibitors Dato-DXd demonstrated a manageable safety profile with no new safety signals. The most common TEAEs were stomatitis, nausea, and fatigue Durable efficacy and manageable safety shown in TROPION-Pan Tumor01 raises confidence in TROPION-Breast01 study BC: breast cancer, BICR: blinded independent central review, DCR: disease control rate, HR: hormone receptor, mPFS: median progression-free survival, ORR: objective response rate, SABCS: San Antonio Breast Cancer Symposium, 23 TEAEs: treatment emergent adverse events#24Best Percent Change in SOD From Baseline by BICR (n=40).% Progression-free survival, % 100 80 60 Dato-DXd 40 20 -------- 0 -20 -40 -80 -80 * Prior Topo I inhibitor-based ADC -100 100- 80- 60- 40- 20- TROPION-PanTumor01 Study SABCS 2022, TNBC Cohort Efficacy Antitumor Responses by BICR (n=40) aPostbaseline tumor assessments were not available for 1 patient at data cutoff. Three patients were not confirmed to have a target lesion per BICR and therefore had a best overall response of non-CR/non-PD. PFS (All Patients) 29/44 (66) Median (95% CI), mo Events n/N (%) 0- All patients 4.4 (3.0-7.3) T T T T 0 3 6 9 12 15 18 21 Time, months Data cutoff: July 22, 2022 Progression-free survival, % 100- 80- 60- 40° 20- PFS (Topo I Inhibitor-Naïve Patients) Median (95% CI), mo Events n/N (%) 0- Topo I inhibitor-naive patients 7.3 (3.0-18.0) 16/30 (53) T T T T 0 3 6 9 12 15 18 21 Time, months TROPION-Pan Tumor01 TNBC Cohort Daiichi-Sankyo Cohort of patients with unresectable or metastatic TNBC (including HER2 low) in Ph1 trial to evaluate safety and efficacy of Dato-DXd. Patients in this cohort. received a median of three lines of treatment for metastatic disease previously. ORR was 32% in all patients (n=44) and 44% in Topo I inhibitor-naïve patients (n=27) with measurable disease; mDOR was 16.8 months in both groups ■mPFS was 4.4 months in all patients and 7.3 months in Topo I inhibitor-naïve patients mOS was 13.5 months in all patients and 14.3 months in Topo I inhibitor-naïve patients ■No cases of ILD, febrile neutropenia, or grade ≥3 diarrhea were reported Results demonstrate encouraging efficacy and manageable safety profile in TNBC and support ongoing TROPION-Breast02 study BICR: blinded independent central review, CI: confidence interval, ILD: interstitial lung disease, mDOR: median duration of response, mOS: median overall survival, mPFS: median progression-free survival, ORR: objective response rate, PFS: progression-free survival, SABCS: San Antonio Breast Cancer Symposium, TNBC: triple-negative breast cancer 24#25Best change from baseline in target lesion size (%) Change in target lesion from baseline (%) Dato-DXd 100- 50- -50 -100 BEGONIA Study SABCS 2022 Efficacy PD-L1 (TAP 10% cutoff) Low High Missing 240 220 200 180 160- 140 120 100 Best Objective Response Complete response Partial response Stable disease RECIST progression Not evaluable RECIST progression at visit 80 60 40 20 0 -20 40 -60 -80 -100 -120 T 0 12 18 24 30 36 42 48 54 60 66 Time (weeks) BEGONIA (Arm7) Daiichi-Sankyo BEGONIA is open-label platform study to evaluate safety and efficacy of durvalumab combined with other novel therapies in 1L advanced/ metastatic TNBC. Combination of durvalumab and Dato-DXd is evaluated in Arm7 Confirmed ORR was 73.6% in 53 evaluable patients, including 4 (7.5%) CR ■Durable responses with 82% patients remaining in response at the data cut off The most common AEs were nausea, stomatitis, and alopecia Dato-DXd + durvalumab demonstrated a tolerable and manageable safety profile Data Cutoff: July 22, 2022 AES: adverse events, CR: complete response, ORR: objective response rate, RECIST: Response Evaluation Criteria in Solid Tumours, SABCS: San Antonio Breast Cancer Symposium, TNBC: triple-negative breast cancer Results demonstrate a compelling response and support further investigation of combination therapies in 1L advanced/ metastatic TNBC and early stage disease 25#26HR+ Status of Clinical Studies in Breast Cancer Neoadjuvant/ Adjuvant 1L 2L 3L HER2+ DESTINY DESTINY -Breast11 -Breast05 DESTINY -Breast09 HER2 low HER2 IHC >0<1+ HER2 IHC O TNBC Pivotal studies only, not exhaustive Daiichi-Sankyo DESTINY -Breast06 DESTINY-Breast02/03 (HER2+) ENHERTUⓇ DESTINY-Breast04 (HER2-low) DESTINY-Breast06 FY2023 H1: TLR anticipated (Post ET, chemo naïve) TROPION-Breast01 Dato-DXd TROPION -Breast03 TROPION -Breast02 DESTINY -Breast04 (HER2-low) In HR+ BC, the line of therapy indicates post-ET setting. TROPION-Breast03 Dec 2022: Study started chemo: chemotherapy, ET: endocrine therapy, HR: hormone receptor, IHC: immunohistochemistry, TLR: top line results, TNBC: triple-negative breast cancer 26#27Status of Clinical Studies in Lung Cancer NSCLC SCLC 1L AGA DESTINY-Lung04 (HER2m) 2L+ HERTHENA-Lung01/02 (EGFRM) HER3-DXd EHHERTUⓇ DESTINY-Lung01/02 (HER2m) TROPION -Lung07 Non- AGA (PD-L1<50%) Dato-DXd +Pembro±Plat TROPION -Lung08 (PD-L1≥50%) Dato-DXd +Pembro Dato-DXd TROPION-Lung01 Monotherapy DS-7300 Daiichi-Sankyo HERTHENA-Lung01 FY2022 Q4: TLR anticipated TROPION-Lung01 FY2023 Q1: TLR anticipated TROPION-Lung07 Jan 2023: Study started Pivotal studies only, not exhaustive Planning study AGA: actionable genomic alteration, EGFRm: EGFR mutated, HER2m: HER2 mutant, NSCLC: non-small cell lung cancer, Pembro: pembrolizumab, Plat: platinum-based chemotherapy, SCLC: small cell lung cancer, TLR: top line results 27#283ADCs Update Alpha Update News Flow Daiichi-Sankyo 28#29DS-5670 Current development status TLR of Ph1/2/3 booster vaccination study obtained in Nov 2022, regulatory submission in Japan achieved in Jan 2023 FY2022 H1 ■ Development of booster vaccination (Original strain) - TLR of Ph1/2/3 study part 2 was obtained in Nov 2022 and primary endpoint was achieved - Regulatory submission in Japan was achieved in Jan 2023 FY2023 H1 H2 H2 Booster vaccination Ph1/2/3 study Primary vaccination Ph3 study Subvariant vaccine Ph3 study Development of primary vaccination (Original strain) - - Sep 2022: Ph3 study started in Japan Primary vaccination Ph3 study Subjects: Healthy adults with no history of COVID-19 vaccination Confirm non-inferiority of neutralizing antibodies against SARS-CoV-2 (original strain) levels in blood for DS-5670 to ComirnatyⓇ ■Development of BA.4-5 subvariant vaccine - Planning to start clinical study in FY2023 H1 The clinical development of DS-5670 is being conducted through "Vaccine development project" promoted by the Japan Agency for Medical Research and Development (AMED) and "Urgent improvement project for vaccine manufacturing systems" supported by the Ministry of Health, Labour and Welfare (MHLW) Daiichi-Sankyo TLR: top line results 29 29#30DS-5670 Dose 1 Dose 2 ComirnatyⓇ Dose 1 Dose 2 Booster vaccination Ph1/2/3 Study Part 2 (non-inferiority verification part) The 26th Annual Meeting of the Japanese Society of vaccinology Dose 3 DS-5670a ok R Dose 3 Dose 3 ComirnatyⓇ DS-5670a Daiichi-Sankyo Non-inferiority verification of DS-5670a against approved mRNA vaccines GMFR ratio (DS-5670a/ ComirnatyⓇ) SpikevaxⓇ R 어 Dose 3 Spikevax® Booster vaccination Ph1/2/3 Study Part 2 (non-inferiority verification part) Subjects: Healthy adults and the elderly subjects who received the primary vaccination (the first and second dose) of approved COVID-19 mRNA vaccine (ComirnatyⓇ or Spikevax ®) in Japan ■Primary endpoint: Geometric mean fold rise (GMFR) of serum neutralizing antibody titer against SARS-CoV-2 (original strain) after four weeks (Day 29) from the administration of study drug Secondary endpoints: Geometric mean titer (GMT) and seroconversion rate of serum neutralizing against SARS-CoV-2 (original strain) after four weeks (Day 29) from the vaccination, etc 0.5 0.67 GMFR ratio (DS-5670a/ Spikevax®) 0.5 0.67 1 1 2 2 GMFR ratio (DS-5670a/Comrnaty® or Spikevax®) of serum neutralizing antibody titer against SARS-CoV-2 on Day 29 was calculated. The result demonstrated non-inferiority of DS-5670a arm to control arms with the two-sided 97.5% lower confidence interval exceeding the non-inferiority margin 0.67. Rates of TEAE and severity of DS-5670a arm were comparable to those of control arms Confirmed efficacy and safety of DS-5670a booster vaccination in subjects who received approved mRNA vaccine as the primary vaccination Verified non-inferiority of DS-5670a booster vaccination in statistical comparison with ComirnatyⓇ and Spikevax ® booster vaccination 30#31Alpha Clinical and Regulatory Progress YESCARTA ® (axicabtagene ciloleucel) (relapsed/refractory large B-cell lymphoma (LBCL), 2L) ■Dec 2022: Approved in Japan TARLIGE® (mirogabalin) (diabetic peripheral neuropathic pain (DPNP)) Jan 2023 Filing accepted in China DS-1211 (Pseudoxanthoma Elasticum (PXE) ) ■Nov 2022 : Ph2 study in PXE patients started DS-2325 (Netherton syndrome) ■Dec 2022: Granted Orphan Drug Designation by FDA Daiichi-Sankyo 31#323ADCs Update Alpha update News Flow Daiichi-Sankyo 32#33FY2022, 2023 News Flow Daiichi-Sankyo As of Jan 2023 Key data readouts EHHERTUⓇ DESTINY-Breast06*: HR positive and HER2 low BC, chemo naïve, Ph3 Planned major publications JSMO (Mar 16-18, 2023) HER3-DXd Ph1 study: EGFR mutated NSCLC • Data update of dose escalation cohort and dose expansion cohort Dato-DXd • FY2023 H1 TROPION-Lung01*: NSCLC, 2/3L, Ph3 • FY2023 Q1 Regulatory decisions ENHERTUⓇ DESTINY-Breast04: HER2 low BC, post chemo, Ph3 JP: FY2022 Q4 . DESTINY-Lung01, 02: HER2 mutant NSCLC, 2L+, Ph2 ⚫ JP: FY2023 H1 • EU: FY2023 H2 HER3-DXd DS-5670 HERTHENA-Lung01: EGFR mutated NSCLC, 3L, registrational Ph2 • FY2022 Q4 Primary vaccination, original strain, Ph3 • FY2023 H1 Planned pivotal study initiation Quizartinib QUANTUM-First AML, 1L, Ph3 • JP/US: FY2023 H1 • EU: FY2023 H2 FLUMISTⓇ (VN-0107) Nasal seasonal influenza vaccine ⚫ JP: FY2022 Q4 DS-5670 COVID-19 mRNA subvariant vaccine, booster study, healthy volunteers, Ph3 • FY2023 H1 Bold: update from FY2022 Q2 AML: acute myeloid leukemia, BC: breast cancer, JSMO: Japanese Society of Medical Oncology, NSCLC: non-small cell lung cancer Timeline indicated is based on the current forecast and subject to change. *Event-driven study 33#34Agenda 1 FY2022 Q3 Financial Results 2 Business Update 3 R&D Update 4 Appendix Daiichi-Sankyo 34#35Major R&D Milestones (3ADCs) Project ENHERTUⓇ Daiichi-Sankyo As of Jan 2023 BC • • • Target Indication [phase, study name] HER2+, 2L [Ph3, DESTINY-Breast03] HER2 low, post chemo [Ph3, DESTINY-Breast04] HER2 low, chemo naïve [Ph3, DESTINY-Breast06] HER2+, 2L [Ph2, DESTINY-Gastric02, EU] HER2 mutant, 2L [Ph2, DESTINY-Lung01, 02] GC • NSCLC • CRC • HER2+, 3L [Ph2, DESTINY-CRC02] FY2022 H2 FY2023 H1 H2 • Approved (JP) • Approved (EU) • Approval anticipated (JP) • Approved (EU) • ⚫ TLR anticipated . Filing accepted (JP/EU) • Approval anticipated (JP) • Approval anticipated (EU) • TLR obtained • 2/3L [Ph3, TROPION-Lung01] NSCLC Dato-DXd • 1L [Ph3, TROPION-Lung07] • Study started BC • TNBC, adjuvant* [Ph3, TROPION-Breast03] • Study started • EGFR mutated, 3L HER3-DXd NSCLC [Registrational Ph2, HERTHENA-Lung01] • TLR anticipated • TLR anticipated Bold: update from FY2022 Q2 BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TLR: Top Line Results, TNBC: triple-negative breast cancer Timeline indicated is based on the current forecast and subject to change. * Adjuvant therapy for patients with TNBC who have residual disease after neoadjuvant therapy 35#36Major R&D Milestones (Alpha) Project Quizartinib TARLIGE® (mirogabalin) DS-1211 • DS-5670 Target Indication [phase, study name] . AML, 1L [Ph3, JP/US/EU/Asia] • DPNP • . PXE [Ph2, US/EU] • COVID-19 mRNA vaccine (original strain), booster vaccination [Ph1/2/3, JP] COVID-19 mRNA vaccine (original strain), primary vaccination [Ph3, JP] As of Jan 2023 FY2022 H2 FY2023 H1 H2 • Approval Approval Filing accepted (US) anticipated (JP/US) anticipated (EU) • Filing accepted • (China) Study Started . • TLR obtained • Filing accepted (JP) TLR anticipated • Study start anticipated . COVID-19 mRNA vaccine (BA.4-5), vaccination [Ph3, JP] FLUMISTⓇ (VN-0107) • Nasal seasonal influenza vaccine [JP] • Approval anticipated (JP) Bold: update from FY2022 Q2 AML: acute myeloid leukemia, DPNP: diabetic peripheral neuropathic pain, PXE: pseudoxanthoma elasticum, TLR: Top Line Results Timeline indicated is based on the current forecast and subject to change Daiichi-Sankyo 36#37Major R&D Pipeline: 3ADCs (US/EU/Asia) HER2+ BC 2L+/1L DESTINY-Breast07 Phase 1 (JP/US) NSCLC, TNBC, BC*1, SCLC, GC, urothelial, esophageal, prostate, etc. TROPION-PanTumor01 (CN) NSCLC, TNBC TROPION-PanTumor02 (US/EU/Asia) TNBC (durvalumab combo) BEGONIA (CN) HER2+ GC 3L DESTINY-Gastric06 (US/EU/Asia) HER2 low BC Chemo naïve/ post chemo DESTINY-Breast08 (JP/US/EU/Asia) HER2+ GC combo, 2L+/1L DESTINY-Gastric03 (EU/Asia) HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03 (US/EU) BC, bladder (nivolumab combo) (US/EU) BC, NSCLC (pembrolizumab combo) (US/EU/Asia) solid tumors. (AZD5305 combo) PETRA (JP/US/EU/Asia) NSCLC (w/o AGA, pembrolizumab combo) TROPION-Lung02 (UP/US/EU) NSCLC (w/o AGA, durvalumab combo) TROPION-Lung04 (JP/US/EU/Asia) solid tumors (AZD5305 combo) PETRA (UP/US/EU/Asia) NSCLC (JP/US) EGFR mutated NSCLC (osimertinib combo) (JP/US) HER3+ BC (JP/US/EU) HER2+ or HER2 mutant NSCLC 2L+ DESTINY-Lung01 (JP/US/EU/Asia) HER2 mutant NSCLC 2L+ DESTINY-Lung02 (CN) HER2 mutant NSCLC 2L+ DESTINY-Lung05 (US/EU/Asia) NSCLC (durvalumab combo) 2L+ HUDSON (JP/US/EU) HER2+ CRC 3L DESTINY-CRC01 (JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02 Phase 2 (JP/US/EU/Asia) endometrial, ovarian, CRPC, GC, CRC combo TROPION-PanTumor03 (JP/US/EU/Asia) NSCLC (w/ AGA) TROPION-Lung05 (US/EU/Asia) TNBC (durvalumab combo) BEGONIA (JP/US/EU/Asia) EGFR mutated NSCLC (osimertinib combo) 2L ORCHARD (UP/US/EU/Asia) EGFR mutated NSCLC 3L HERTHENA-Lung01 Phase 3 (JP/US/EU/Asia) HER2+ BC 3L DESTINY-Breast02 As of Jan 2023 (CN) HER2+ BC 2L DESTINY-Breast03 Filed (JP/US/EU/Asia) HER2+ BC adjuvant*2 DESTINY-Breast05 (JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06 (JP/US/EU/Asia) HER2+ BC 1L DESTINY-Breast09 (JP/CN) HER2 low BC post chemo DESTINY-Breast04 (JP/EU) HER2 mutant NSCLC 2L+ DESTINY-Lung01/Lung02 (JP/US/EU/Asia) HER2+ BC neoadjuvant DESTINY-Breast11 (JP/EU/Asia) HER2+ GC 2L DESTINY-Gastric04 ENHERTUⓇ Dato-DXd HER3-DXd (JP/US/EU/Asia) HER2 mutant tumor DESTINY-Pan Tumor01 (US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02 Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials Breakthrough Designation (US) *1 HR+, HER2 low or negative BC Orphan drug designation (JP) *2 Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy *3 Adjuvant therapy for TNBC patients with residual invasive disease following neoadjuvant therapy AGA: actionable genomic alterations, BC: breast cancer, CRPC: castration-resistant prostate cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer (JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L DESTINY-Lung04 (UP/US/EU/Asia) NSCLC 2/3L TROPION-Lung01 (JP/US/EU/Asia) non-squamous NSCLC (w/o AGA, pembrolizumab combo) 1L TROPION-Lung07 (JP/US/EU/Asia) NSCLC (w/o AGA, pembrolizumab combo) 1L TROPION-Lung08 (JP/US/EU/Asia) BC*1 2/3L TROPION-Breast01 (UP/US/EU/Asia) TNBC 1L TROPION-Breast02 (JP/US/EU/Asia) TNBC (mono or durvalumab combo) adjuvant*³ TROPION-Breast03 (JP/US/EU/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung02 Daiichi-Sankyo 37#38Major R&D Pipeline: Alpha DS-7300 (JP/US) B7-H3-directed ADC ESCC, CRPC, squamous NSCLC, SCLC, etc. DS-6000 (JP/US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer DS-1055 (JP/US) Anti-GARP antibody Solid tumors DS-1594 (US) Menin-MLL binding inhibitor AML, ALL DS-9606 (US/EU) Target undisclosed ADC Solid tumors Phase 1 DS-6016 (JP) Anti-ALK2 antibody FOP DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus DS-2325 (US) KLK5 inhibitor Netherton syndrome As of Jan 2023 Daiichi-Sankyo Phase 2 Valemetostat (DS-3201)(JP/US/EU/Asia) EZH1/2 inhibitor PTCL Valemetostat (DS-3201) (EU) EZH1/2 inhibitor BCL DS-1001 (JP) Mutant IDH1 inhibitor Glioma DS-7300 (JP/US/EU/Asia) B7-H3-directed ADC ES-SCLC DS-5141 (JP) ENA oligonucleotides DMD DS-1211 (US/EU) TNAP inhibitor Pseudoxanthoma elasticum DS-5670 (JP) COVID-19 mRNA vaccine, COVID-19 (primary vaccination, 5 to 11 aged children) (in prep.) VN-0200 (JP) RS virus vaccine RS virus infection Phase 3 Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor Esaxerenone (JP) MR blocker Diabetic nephropathy VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine DS-5670 (JP) COVID-19 mRNA vaccine (original strain) COVID-19 (primary vaccination, adults) DS-5670 (JP) COVID-19 mRNA vaccine (original strain), COVID-19 (primary vaccination, 12 to 17 aged children) Quizartinib (JP/US/EU) FLT3 inhibitor AML 1L Mirogabalin (CN) a28 ligands Filed Diabetic peripheral neuropathic pain VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray DS-5670 (JP) COVID-19 mRNA vaccine (original strain). COVID-19 (booster vaccination) Oncology Specialty medicine Vaccine Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials SAKIGAKE Designation (JP) Orphan drug designation (designated in at least one country/region among JP, US and EU) ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressiva, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma 38#39Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1125 Email: Daiichi [email protected]